| Choice Physical Therapy Llc | |
|
1 Blanchard Court, Montpelier, VT 05602 | |
| (802) 229-6398 | |
| (802) 229-5137 |
| Full Name | Choice Physical Therapy Llc |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 1 Blanchard Court, Montpelier, Vermont |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730148297 | NPI | - | NPPES |
| OVN2233 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 0400003183 (Vermont) | Primary |
| Provider Name | Elliott Morse |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1639112709 PECOS PAC ID: 7012176571 Enrollment ID: I20120302000335 |
News Archive
A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.
University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Colorado's governor says the state will continue to build its insurance exchange and to advance other elements of the health law regardless of the Supreme Court's ruling. Meanwhile, Alabama's attorney general predicts the court will strike down the law.
The professor of the Faculty of Medicine and Dentistry of the University of Valencia Carlos Camps has participated in a research that advances in the search for biomarkers that may predict lung cancer.
› Verified 9 days ago
| Provider Name | Lauren Cook |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1114989720 PECOS PAC ID: 1951378462 Enrollment ID: I20120302000392 |
News Archive
A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.
University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Colorado's governor says the state will continue to build its insurance exchange and to advance other elements of the health law regardless of the Supreme Court's ruling. Meanwhile, Alabama's attorney general predicts the court will strike down the law.
The professor of the Faculty of Medicine and Dentistry of the University of Valencia Carlos Camps has participated in a research that advances in the search for biomarkers that may predict lung cancer.
› Verified 9 days ago
| Provider Name | Maryellen Boutin |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427090521 PECOS PAC ID: 4880853340 Enrollment ID: I20120302000397 |
News Archive
A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.
University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Colorado's governor says the state will continue to build its insurance exchange and to advance other elements of the health law regardless of the Supreme Court's ruling. Meanwhile, Alabama's attorney general predicts the court will strike down the law.
The professor of the Faculty of Medicine and Dentistry of the University of Valencia Carlos Camps has participated in a research that advances in the search for biomarkers that may predict lung cancer.
› Verified 9 days ago
| Provider Name | Maureen Fraser |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1386686483 PECOS PAC ID: 6608035175 Enrollment ID: I20120302000408 |
News Archive
A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.
University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Colorado's governor says the state will continue to build its insurance exchange and to advance other elements of the health law regardless of the Supreme Court's ruling. Meanwhile, Alabama's attorney general predicts the court will strike down the law.
The professor of the Faculty of Medicine and Dentistry of the University of Valencia Carlos Camps has participated in a research that advances in the search for biomarkers that may predict lung cancer.
› Verified 9 days ago
| Provider Name | Jasmine Braman |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1336617562 PECOS PAC ID: 2769726421 Enrollment ID: I20181206001432 |
News Archive
A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.
University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Colorado's governor says the state will continue to build its insurance exchange and to advance other elements of the health law regardless of the Supreme Court's ruling. Meanwhile, Alabama's attorney general predicts the court will strike down the law.
The professor of the Faculty of Medicine and Dentistry of the University of Valencia Carlos Camps has participated in a research that advances in the search for biomarkers that may predict lung cancer.
› Verified 9 days ago
| Provider Name | Pamela Robichaud |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1023232899 PECOS PAC ID: 0042623662 Enrollment ID: I20201228002123 |
News Archive
A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.
University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Colorado's governor says the state will continue to build its insurance exchange and to advance other elements of the health law regardless of the Supreme Court's ruling. Meanwhile, Alabama's attorney general predicts the court will strike down the law.
The professor of the Faculty of Medicine and Dentistry of the University of Valencia Carlos Camps has participated in a research that advances in the search for biomarkers that may predict lung cancer.
› Verified 9 days ago
| Provider Name | Ashley N Kubit |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699419382 PECOS PAC ID: 7810375821 Enrollment ID: I20220603000701 |
News Archive
A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.
University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Colorado's governor says the state will continue to build its insurance exchange and to advance other elements of the health law regardless of the Supreme Court's ruling. Meanwhile, Alabama's attorney general predicts the court will strike down the law.
The professor of the Faculty of Medicine and Dentistry of the University of Valencia Carlos Camps has participated in a research that advances in the search for biomarkers that may predict lung cancer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Choice Physical Therapy Llc Po Box 693, Williston, VT 05495 Ph: (802) 878-6656 | Choice Physical Therapy Llc 1 Blanchard Court, Montpelier, VT 05602 Ph: (802) 229-6398 |
News Archive
A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.
University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Colorado's governor says the state will continue to build its insurance exchange and to advance other elements of the health law regardless of the Supreme Court's ruling. Meanwhile, Alabama's attorney general predicts the court will strike down the law.
The professor of the Faculty of Medicine and Dentistry of the University of Valencia Carlos Camps has participated in a research that advances in the search for biomarkers that may predict lung cancer.
› Verified 9 days ago
Mrs. Lori Rae Rose, R.P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 81 River St, Ste 201, Montpelier, VT 05602 Phone: 802-262-1500 | |
Zippy Life Physical Therapy, Pllc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 111 Essex Way, Montpelier, VT 05602 Phone: 802-522-3615 Fax: 802-613-1009 | |
Mrs. Maryellen Willette Boutin, PHYSICAL THERAPIST Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1 Blanchard Court, Montpelier, VT 05602 Phone: 802-229-6398 Fax: 802-229-5137 | |
Mr. James Theodore Lamb, PHYSICAL THERAPIST Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 81 River St, Suite 201, Montpelier, VT 05602 Phone: 802-262-1500 Fax: 802-262-1505 | |
Dr. Liliane Beaudoin Savard, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 111 Essex Way, Montpelier, VT 05602 Phone: 802-522-3615 Fax: 802-613-1009 | |
Julie Pauline Giffin, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 222 Berlin St, Montpelier, VT 05602 Phone: 802-223-1393 |